Our Take
This is a CDMO vendor backgrounder dressed as a primer, and it's useful precisely because it names the three failure modes that matter: regulatory shortcomings in analytics, botched tech transfers, and demand forecasting, not hype.
Why it matters
Gene therapy developers lose months or years and investor confidence when late-stage programs fail. The field has only 24 approved viral vector therapies despite hundreds in pipelines, so understanding where programs derail—and how to avoid it—directly affects which therapies reach patients and which don't.
Do this week
If you're managing a late-stage viral vector program: audit your potency assays and stability data against current FDA expectations now, before BLA submission, rather than discovering gaps during regulatory review.
Three failure modes kill late-stage viral vector programs
Developers advancing cell and gene therapies face heightened regulatory scrutiny at late stage because early manufacturing missteps—failed batches, process variability, analytics gaps—cascade into costly rework that can trigger additional toxicology studies or outright BLA rejection.
Regulatory risk comes in three forms. First: process gaps. Developers often push early-stage manufacturing protocols into late-phase development without the robustness regulators now demand. Second: analytical shortcomings. Standard methods like ELISA for capsid titer and qPCR for genomic titer no longer satisfy FDA expectations for AAV and lentiviral vector characterization; regulators now expect potency assays, stability packages, and advanced characterization that legacy methods cannot deliver. Third: supply chain traceability. Documentation, sourcing records, and stability data from earlier stages now face intense scrutiny and often fail to meet current standards, triggering follow-up questions and delays.
Operational failures compound these risks. Tech transfer from developer to CDMO requires gap assessment, protocol alignment, block flow diagrams, bill of materials, raw material specs, and qualified assays. Production interruptions (supply chain gaps, regulatory holds) halt manufacturing entirely. Batch losses from suboptimal growth conditions, purification challenges, or scale-up issues compound delays further.
Market risk sits outside developer and CDMO control. The AAV sector illustrates this: after regulatory approval surge, high-dose fatalities prompted FDA to increase scrutiny while investor confidence eroded. Developers now pursue lower-dose strategies and improved target specificity rather than raw efficacy gains, shifting demand unpredictably.
Only 24 viral vector therapies approved despite hundreds in pipelines
With 24 approved viral vector gene therapies and hundreds more advancing through clinical pipelines, the bottleneck is not science but execution at late stage. A single regulatory hold, failed batch, or supply interruption jeopardizes patient access and erodes investor confidence. Developers with manufacturing support must choose a CDMO with expertise in regulatory strategy, process validation, and operational resilience to guide programs to commercial launch.
The cost of failure is absolute: late-stage programs cannot restart from earlier checkpoints. A misstep unravels months or years of progress and investor capital.
What to demand from your CDMO partner
Select a CDMO with proven experience across the full life cycle, not just one phase. Lonza, for example, has supported over 90 diverse viral vector programs across preclinical, clinical, and commercial stages, with integrated process development and manufacturing under one roof to accelerate tech transfer.
Require strong regulatory readiness: the CDMO must anticipate BLA gaps before regulators flag them, use advanced analytics to characterize vectors and strengthen submissions, and engage agencies proactively. Demand GMP-compliant facilities that have passed multiple FDA and EMA inspections, with validated cleaning processes, proper virus segregation, and Part 11-compliant systems.
Insist on capacity flexibility. Commercial demand in gene therapy shifts rapidly—a CDMO must be able to flex manufacturing, staffing, and facility design based on anticipated need rather than forcing you into fixed agreements that become liabilities if market conditions shift.